<header id=000338>
Published Date: 2022-10-07 08:54:18 EDT
Subject: PRO/AH/EDR> Monkeypox update (83) case counts, intradermal vaccination
Archive Number: 20221007.8706012
</header>
<body id=000338>
MONKEYPOX UPDATE (83) CASE COUNTS, INTRADERMAL VACCINATION
**********************************************************
A ProMED-mail post
http://www.promedmail.org
ProMED-mail is a program of the
International Society for Infectious Diseases
http://www.isid.org

In this update:
[1] Cases around the world
[2] USA: cases by state
[3] USA: disproportionate case and vaccination numbers
[4] Intradermal vaccination

******
[1] Cases around the world
Date: Thu 6 Oct 2022 17:00 EDT
Source: Centers for Disease Control and Prevention (CDC) [edited]
https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html


Confirmed and suspected cases by country as of 6 Oct 2022

Country / Cases
---------------
Andorra / 4
Argentina / 396
Aruba / 3
Australia / 138
Austria / 314
Bahamas / 2
Bahrain / 1
Barbados / 1
Belgium / 775 (1 fatal)
Benin / 3
Bermuda / 1
Bolivia / 210
Bosnia and Herzegovina / 5
Brazil / 8147 (3 fatal)
Bulgaria / 6
Cameroon / 8 (2 fatal)
Canada / 1406
Central African Republic / 9
Chile / 977
China / 1
Colombia / 2453
Costa Rica / 6
Croatia / 29
Cuba / 4 (1 fatal)
Curacao / 3
Cyprus / 5
Czechia / 68 (1 fatal)
Dem Republic Congo / 190
Denmark / 187
Dominican Republic / 31
Ecuador / 142 (1 fatal)
Egypt / 1
El Salvador / 9
Estonia / 11
Finland / 40
France / 4043
Georgia / 2
Germany / 3640
Ghana / 103 (4 fatal)
Gibraltar / 6
Greece / 82
Greenland / 2
Guadeloupe / 1
Guatemala / 32
Guyana / 2
Honduras / 6
Hong Kong / 1
Hungary / 78
Iceland / 14
India / 12 (1 fatal)
Indonesia / 1
Iran / 1
Ireland / 195
Israel / 254
Italy / 851
Jamaica / 14
Japan / 6
Jordan / 1
Latvia / 5
Lebanon / 11
Liberia / 3
Lithuania / 5
Luxembourg / 55
Malta / 33
Martinique / 1
Mexico / 1968
Moldova / 2
Monaco / 3
Montenegro / 2
Morocco / 3
Netherlands / 1221
New Caledonia / 1
New Zealand / 9
Nigeria / 400 (7 fatal)
Norway / 92
Panama / 16
Paraguay / 2
Peru / 2587
Philippines / 4
Poland / 195
Portugal / 926
Qatar / 5
Republic of the Congo / 5
Romania / 40
Russia / 2
St Martin / 1
Saudi Arabia / 8
Serbia / 40
Singapore / 19
Slovakia / 14
Slovenia / 47
South Africa / 5
South Korea / 2
Spain / 7209 (3 fatal)
Sudan / 17 (1 fatal)
Sweden / 198
Switzerland / 516
Taiwan / 3
Thailand /10
Turkey / 1
Ukraine / 4
United Arab Emirates / 16
United Kingdom / 3654
United States / 26 385 (2 fatal)
Uruguay / 9
Venezuela / 8
Viet Nam / 1

Total confirmed cases: 70 696
Total deaths: 27

--
Communicated by:
ProMED

******
[2] USA: cases by state
Date: Thu 6 Oct 2022 14:00 EDT
Source: Centers for Disease Control and Prevention (CDC) [edited]
https://www.cdc.gov/poxvirus/monkeypox/response/2022/us-map.html


The US CDC reports cases in the following states:
State / Number of cases
-----------------------
Alabama / 130
Alaska / 5
Arizona / 478
Arkansas / 60
California / 5010
Colorado / 291
Connecticut / 131
Delaware / 39
District of Columbia / 498
Florida / 2565*
Georgia / 1832
Hawaii / 34
Idaho / 14
Illinois / 1331
Indiana / 237
Iowa / 25
Kansas / 14
Kentucky / 59
Louisiana / 263
Maine / 9
Maryland / 677
Massachusetts / 409
Michigan / 279
Minnesota / 206
Mississippi / 91
Missouri / 125
Montana / 6
Nebraska / 30
Nevada / 267
New Hampshire / 30
New Jersey / 721
New Mexico / 43
New York / 3976
North Carolina / 594
North Dakota / 6
Ohio / 285
Oklahoma / 46
Oregon / 223
Pennsylvania / 789
Puerto Rico / 184
Rhode Island / 78
South Carolina / 182
South Dakota / 2
Tennessee / 314
Texas / 2410
Utah / 168
Vermont / 3
Virginia / 500
Washington / 615
West Virginia / 12
Wisconsin / 82
Wyoming / 4
[Non-US resident / 3]

Total confirmed monkeypox/orthopoxvirus cases: 26 385

*One Florida case is listed here but included in the United Kingdom case counts because the individual was tested while in the UK.

--
Communicated by:
ProMED

******
[3] USA: disproportionate case and vaccination numbers
Date: Thu 6 Oct 2022
Source: CIDRAP (Center for Infectious Disease Research and Policy) News [edited]
https://www.cidrap.umn.edu/news-perspective/2022/10/report-monkeypox-case-rates-5-times-higher-black-americans


A new report from the Kaiser Family Foundation (KFF) based on Centers for Disease Control (CDC) data reveals that monkeypox case rates in the US disproportionately affect Black and Latino Americans, with Black Americans having case rates 5 times those found among White peers (14.4 cases vs. 2.6 per 100 000).

"Native Hawaiian and Other Pacific Islander (NHOPI) and Hispanic people also have significantly higher rates of reported MPX cases at 10.0 and 8.3 per 100 000, respectively. Rates are lower and similar for Asian (3.0 per 100 000), American Indian and Alaska Native (AIAN) (2.8 per 100,000), and White (2.6 per 100 000) people," the report reads.

The statistics are based on CDC data on 68% of cases reported in the United States as of 23 Sep [2022]. The monkeypox outbreak in the US has slowed considerably since its peak activity in July [2022], but new cases are still disproportionality seen in minorities. Of cases with known race or ethnicity, 70% are among people of color, despite representing only 40% of the population. White people account for 30% of cases and 60% of the US population.

Racial inequity is also at play in monkeypox vaccine distribution. "As of 27 Sep [2022], over half (51%) of MPX 1st doses of vaccinations have gone to White people, although they represent 30% of reported cases," KFF said. "In contrast, despite accounting for more than 1/3 of cases (35%), only 13% of 1st doses administered went to Black people."

Yesterday [5 Oct 2022] the CDC reported 117 more monkeypox cases, putting the national total at 26 311.

More states, cities expand vaccine access
-----------------------------------------
As the pace of the monkeypox outbreak slows across the country, more states and cities are expanding monkeypox vaccine eligibility to include more people at risk, such as sex partners of anyone previously eligible.

In Las Vegas, the Southern Nevada Health District has opened access to sex partners of anyone previously eligible for the vaccine or who anticipates experiencing other risk factors.

In Wisconsin, access has opened to men who have sex with men who have a new diagnosis of a sexually transmitted infection in the past year, or people who have attended a commercial sex venue in the past year.

--
Communicated by:
Mary Marshall
<mjm2020@googlemail.com>

[The KFF report is available at https://www.kff.org/racial-equity-and-health-policy/issue-brief/national-data-show-continuing-disparities-in-mpx-monkeypox-cases-and-vaccinations-among-black-and-hispanic-people/]

******
[4] Intradermal vaccination
Date: Wed 4 Oct 2022
Source: American Association of Pharmaceutical Scientists (AAPS) Journal [edited]
https://link.springer.com/content/pdf/10.1208/s12248-022-00754-6.pdf


Citation: Mrsny RJ. Does an intradermal vaccination for monkeypox make sense? AAPS J. 2022; 24(6): 104
--------------------------------------------------------------------------------
Abstract
--------
Mankind has recently had to deal with a series of virus-mediated pandemics, resulting in extensive morbidity and mortality rates that have severely strained healthcare systems. While dealing with viral infections as a healthcare concern is not new, our exceptionally mobile society has added to the critical challenge of limiting pathogen spread of a highly transmissible virus prior to the generation, testing, and distribution of safe and effective vaccines. The tremendous global effort put forth to address the recent pandemic induced by SARS-CoV-2 infection has highlighted many of the strengths and weaknesses of how vaccines are identified, tested, and used to provide protection. These uncertainties are exacerbated by the lack of clear and consistent messaging that can occur when the processes of research, development, and clinical testing that normally require years of study and consideration are compressed into a few months. In this commentary, I will provide some background on the intramuscular (IM), subcutaneous (SC), and intradermal (ID) administration routes used for injectable vaccines and some information on potential immunological outcomes. With this background, I will address the recent FDA decision to allow an approved vaccine against monkeypox virus to be administered by ID, as well as its initial approval route via SC, injection as a dose-sparing strategy to maximize immunization numbers using current stockpiles.

Summary
There is a rich milieu of immune-related cell types that reside in or circulate through the dermis that can generate both adaptive and innate responses: macrophages, mast cells, Langerhans cells, and dermal dendritic cells [13]. Indeed, the antigen-presenting capabilities of this repertoire of cells in the dermis can result in immune responses that are superior to other anatomical sites, with less vaccine material [14]. As ID injections are well-known for a robust immune response, this delivery strategy has been proposed for a number of vaccines, including those targeting influenza [15] and SARS-CoV-2 [16] viruses. With the promise of ID vaccination but with the challenges of efficient immunization expertise by healthcare personnel, it is not surprising that great efforts have been made to develop systems and devices to simplify and standardize these administrations [17]. Using such approaches to make ID immunization as simple as current IM or SC injections would dramatically benefit the global effort to address pathogen outbreaks to maximize the number of patients reached while minimizing the burden of vaccine manufacturing and stockpiling. Most of these approaches would also address the concern that, despite the reduced volume required for injection, the relative proportion of vaccine wastage in the dead space of the needle and syringe is increased for ID compared to the larger volumes of SC or IM injection [18].

While guidance changes issued by the FDA are frequently based upon more than a single clinical trial outcome, changing the route of the JYNNEOS vaccine from SC to an ID injection as a dose-sparing strategy is supported by robust, well-controlled clinical data and sound immunological principles. The challenge, however, will be to ensure that patients receiving these ID vaccines have a positive experience during the administration process and benefit from a properly performed injection. To successfully meet this challenge, we will need to carry out a mass immunization program where healthcare professionals who are sufficiently trained in the Mantoux technique administer these vaccines. As ID vaccines gain acceptance by patients following positive vaccination experiences, advantages to this approach for global immunization programs will lead to clinical testing and acceptance for ID injection systems and devices. Both outcomes would hopefully limit monkeypox vaccine skepticism and disinformation like that recently seen for SARS-CoV-2 vaccines. Healthcare approaches to address the COVID-19 disease induced by the SARS-CoV-2 virus have provided a good example of how an insufficient understanding of viral pathogenicity and the requirements for mechanism(s) of immune-induced protection can result in skepticism and disinformation that suppressed vaccine acceptance by the public.

--
Communicated by:
Roland HÃ¼bner
<roland.hubner@health.fgov.be>

[The full article and references are available at the source URL above.]
See Also
Monkeypox update (82) 20221006.8705986
Monkeypox update (81) 20221005.8705969
Monkeypox update (80) 20221004.8705948
Monkeypox update (79) 20221002.8705892
Monkeypox update (78) 20220930.8705872
Monkeypox update (77) 20220930.8705860
Monkeypox update (76) 20220928.8705838
Monkeypox update (75) 20220927.8705819
Monkeypox update (74) 20220924.8705776
Monkeypox update (73) 20220923.8705754
Monkeypox update (72) 20220923.8705724
Monkeypox update (71) 20220921.8705707
Monkeypox update (70) 20220920.8705683
Monkeypox update (69) 20220918.8705645
Monkeypox update (68) 20220916.8705606
Monkeypox update (67) 20220915.8705593
Monkeypox update (66) 20220913.8705561
Monkeypox update (65) 20220912.8705540
Monkeypox update (64) 20220911.8705520
Monkeypox update (63) 20220909.8705485
Monkeypox update (62) 20220908.8705464
Monkeypox update (61) 20220907.8705448
Monkeypox update (60) 20220903.8705384
Monkeypox update (59) 20220902.8705359
Monkeypox update (58) 20220901.8705343
Monkeypox update (57) 20220831.8705323
Monkeypox update (56) 20220830.8705307
Monkeypox update (55) 20220827.8705264
Monkeypox update (54) 20220826.8705244
Monkeypox update (53) 20220825.8705221
Monkeypox update (52) 20220824.8705202
Monkeypox update (51) 20220823.8705186
Monkeypox update (50) 20220822.8705162
Monkeypox update (49) 20220819.8705105
Monkeypox update (48) 20220818.8705083
Monkeypox update (47) 20220817.8705070
Monkeypox update (46) 20220815.8705047
Monkeypox update (45): animal, France, human-to-dog transmission 20220814.8705030
Monkeypox update (44) 20220808.8704938
Monkeypox update (43) 20220806.8704878
Monkeypox update (42) 20220731.8704781
Monkeypox update (41) 20220730.8704763
Monkeypox update (40) 20220729.8704747
Monkeypox update (39) 20220726.8704672
Monkeypox update (38) 20220725.8704644
Monkeypox update (37) 20220724.8704627
Monkeypox update (36) 20220723.8704611
Monkeypox update (35) 20220722.8704591
Monkeypox update (34) 20220721.8704565
Monkeypox update (33) 20220720.8704536
Monkeypox update (32) 20220718.8704495
Monkeypox update (31) 20220715.8704451
Monkeypox update (30) 20220714.8704415
Monkeypox update (29) 20220713.8704398
Monkeypox update (28) 20220712.8704375
Monkeypox update (27) 20220711.8704351
Monkeypox update (26) 20220709.8704318
Monkeypox update (25) 20220708.8704301
Monkeypox update (24) 20220707.8704281
Monkeypox update (23) 20220706.8704264
Monkeypox update (22) 20220705.8704244
Monkeypox update (21) 20220704.8704226
Monkeypox update (20) 20220701.8704175
Monkeypox update (19) 20220630.8704136
Monkeypox update (18) 20220627.8704101
Monkeypox update (17) 20220625.8704069
Monkeypox update (16) 20220623.8704027
Monkeypox update (15) 20220622.8704003
Monkeypox update (14) 20220618.8703943
Monkeypox update (13) 20220616.8703901
Monkeypox update (12) 20220613.8703840
Monkeypox update (11) 20220610.8703793
Monkeypox update (10) 20220607.8703721
Monkeypox update (09) 20220604.8703670
Monkeypox update (08) 20220531.8703603
Monkeypox update (07) 20220531.8703592
Monkeypox update (06) 20220530.8703569
Monkeypox update (05) 20220527.8703493
Monkeypox update (04) 20220526.8703477
Monkeypox update (03) 20220526.8703465
Monkeypox update (02) 20220524.8703425
Monkeypox update (01) 20220521.8703393
.................................................ty/mj/jh
</body>
